LEADER 03950nam  2200649 a 450 
001 9910139738303321
005 20240514074606.0
010   $a1-283-40690-X
010   $a9786613406903
010   $a1-119-99862-X
010   $a1-119-99863-8
035   $a(CKB)2550000000074154
035   $a(EBL)822610
035   $a(OCoLC)768732463
035   $a(SSID)ssj0000550887
035   $a(PQKBManifestationID)12189041
035   $a(PQKBTitleCode)TC0000550887
035   $a(PQKBWorkID)10524273
035   $a(PQKB)10936320
035   $a(MiAaPQ)EBC822610
035   $a(Au-PeEL)EBL822610
035   $a(CaPaEBR)ebr10518670
035   $a(CaONFJC)MIL340690
035   $a(EXLCZ)992550000000074154
100   $a20110725d2012      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aAdvances in combination therapy for asthma and COPD /$feditor, Jan Lo?tvall
205   $a3rd ed.
210   $aChichester, West Sussex $cJohn Wiley & Sons$d2012
215   $a1 online resource (366 p.)
300   $aDescription based upon print version of record.
311   $a0-470-72702-0 
320   $aIncludes bibliographical references and index.
327   $aSimilarities and differences in the pathophysiology of asthma and COPD / Christian Virchow -- Glucocorticoids : pharmacology and mechanisms / Peter Barnes -- Inhaled corticosteroids ? clinical effects in asthma and COPD / Paul O'Byrne -- LABAS : pharmacology, mechanisms and interaction with anti-inflammatory treatments /  Gary Anderson -- Long and ultra-long acting beta-2-agonists / Mario Cazzola -- The safety of long-acting beta agonists and the development of combination therapies for asthma and chronic obstructive pulmonary disease / Eugene Bleecker -- Inhaled combination therapy with glucocorticoids and long-acting beta-2-agonists in asthma and COPD, current and future perspectives / Jan Lotvall -- Novel anti-inflammatory treatments for asthma and COPD / Ian Adcock -- Novel biologicals alone and in combination in asthma and allergy / William Busse -- Anti-infective treatments in asthma and COPD / Jonathan D.R. Macintyre & Sebastian L. Johnston -- Long acting muscarinic antagonists in asthma and COPD / Denis O'Donnell -- Phosphodiesterase inhibitors in obstructive lung disease / Jan Lotvall -- Biological therapies in development for COPD / Riccardo Polosa -- Triple therapy?, in the management of chronic obstructive lung disease (COPD). The value of combination treatment with inhaled steroid, long acting anticholinergicbronchodilator and long acting beta 2 agonist bronchodilator in COPD / Ronald Dahl.
330   $aAimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion.  A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combi
606   $aLungs$xDiseases, Obstructive$xChemotherapy
606   $aAsthma$xChemotherapy
606   $aPolypharmacy
606   $aChemotherapy, Combination
615  0$aLungs$xDiseases, Obstructive$xChemotherapy.
615  0$aAsthma$xChemotherapy.
615  0$aPolypharmacy.
615  0$aChemotherapy, Combination.
676   $a616.2/3061
701   $aLo?tvall$b Jan$0889317
701   $aBusse$b W. W$g(William W.)$0889318
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910139738303321
996   $aAdvances in combination therapy for asthma and COPD$91986803
997   $aUNINA